Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer

Cancer Immunol Immunother. 2007 Jun;56(6):905-11. doi: 10.1007/s00262-006-0248-1. Epub 2006 Nov 15.


Non-specific immunopotentiators, such as polysaccharide K (PSK), also known as OK-432, induce anti-tumor effects via immunological responses. The efficacy of combination immunochemotherapy using these immunopotentiators has been examined by multiple previous studies. The survival benefits of immunochemotherapy for patients with curative resections of gastric cancers are not widely accepted. To clarify this issue, we performed a meta-analysis to evaluate the effect of immunochemotherapy on survival in patients with curative resections of gastric cancer. For this study, we compared the results of chemotherapy and immunotherapy using the biological response modifier PSK as an immunopotentiator. The meta-analysis included 8,009 patients from eight randomized controlled trials after central randomization. The overall hazard ratio for eligible patients was 0.88 (95% confidence interval, 0.79-0.98; P = 0.018) with no significant heterogeneity [chi (2)(8) for heterogeneity = 11.7; P = 0.16]. The results of this meta-analysis suggest that adjuvant immunochemotherapy with PSK improves the survival of patients after curative gastric cancer resection.

Publication types

  • Meta-Analysis

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Antineoplastic Agents / therapeutic use
  • Chemotherapy, Adjuvant
  • Humans
  • Immunotherapy
  • Picibanil / immunology
  • Picibanil / therapeutic use*
  • Polysaccharides, Bacterial / immunology
  • Polysaccharides, Bacterial / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / surgery*
  • Survival Analysis


  • Adjuvants, Immunologic
  • Antineoplastic Agents
  • Polysaccharides, Bacterial
  • Picibanil